When was Genenta Science founded?

Genenta Science was founded in 2014.

Where is Genenta Science located?

Genenta Science is located in Milan, Italy .

Who is the current CEO of Genenta Science?

Pierluigi Paracchi is the current CEO of Genenta Science.

When was the latest funding round of Genenta Science?

Genenta Science's latest funding round was on Mar 19, 2025.

Where does Genenta Science rank among its competitors?

Genenta Science ranks 240 amongst 3172 active competitors.

Who are the top competitors of Genenta Science?

Genenta Science's top competitors are Jazz Pharmaceuticals, Moderna and BeiGene.

Genenta Science - 2025 Company Profile, Funding & Competitors

Genenta Science is a public company based in Milan (Italy), founded in 2014 by , and . It operates as a Developer of lentivirus-based gene and cell therapies for cancer. Genenta Science has raised $33.6M in funding from and Mediobanca. The company has 3172 active competitors, including 1104 funded and 755 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Moderna and BeiGene.

Company Details

Developer of lentivirus-based gene and cell therapies for cancer. The lead candidateTemferon is a lentivirus-based hematopoietic stem progenitor cell immuno-gene therapy for Glioblastoma, solid tumor, and hematological malignancies. Also, has Tie2-Expressing Monocytes immunotherapies for multiple cancer treatment.

Website
Social

Key Metrics

Founded Year

2014

Location

Milan, Italy

Stage

Public

Total Funding

in 4 rounds

Latest Funding Round

Investors

& 4 more

Ranked

240^th among

Similar Companies

Jazz Pharmaceuticals &

Exit Details

Public

Get your free copy of Genenta Science's company profile

Genenta Science has raised a total funding of $33.6M over 4 rounds. Its first funding round was on Mar 05, 2015. Its latest funding round was a Post IPO round on Mar 19, 2025 for $21.9M. 1 investor participated in its latest round, which include iStarter, Growth Engine, Mediobanca and ENEA Tech e Biomedical.

Genenta Science has 5 institutional investors including , Mediobanca and .

Here is the list of recent funding rounds of Genenta Science:

Date of funding	Funding Amount	Round Name	Post money valuation	Revenue multiple	Investors
Mar 19, 2025	$21.9M	Post IPO	7618033	1169954	ENEA Tech e Biomedical
Sep 11, 2019	$14.6M	Series C	4422149	2075630
Sep 13, 2017	$8M	Series B	1370701	8529133	-

Access funding benchmarks and valuations. Sign up today!

View details of Genenta Science's funding rounds and investors

The founders of Genenta Science are , and . is the CEO of Genenta Science. has founded 3 more companies - Axon Partners Group, Aurora Science and Altheia Science.

View details of Genenta Science's Founder profiles and Board Members

Top competitors of Genenta Science include Jazz Pharmaceuticals, Moderna and BeiGene. Here is the list of Top 10 competitors of Genenta Science, ranked by 秘密研究所 score :

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of therapeutics for cancer and neurological disorders	$265M	InterWest Partners, Versant Ventures听&补尘辫;听	86/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Flagship Pioneering, Wellington听&补尘辫;听	85/100
3rd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	T. Rowe Price, Temasek听&补尘辫;听	84/100
4th	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	HBM Partners, Seventure Partners听&补尘辫;听	83/100
5th	Recursion 2013, United States, Public	R&D based company focused on manufacturing of drugs for multiple therapeutic areas	$452M	HTIF, Menlo Ventures听&补尘辫;听	81/100
6th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Deerfield听&补尘辫;听	81/100
7th	Incyte 1991, Wilmington (United States), Public	Developer of small molecules for the treatment of different cancer and skin diseases	-	Tekla Capital Management, BB Biotech听&补尘辫;听	78/100
8th	Revolution Medicines 2014, Redwood City (United States), Public	Developer of therapies for treating cancer	$181M	Deerfield, HTIF听&补尘辫;听	78/100
9th	Blueprint Medicines 2008, Cambridge (United States), Public	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Foresite Capital, Roche听&补尘辫;听	77/100
10th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Aisling Capital, Frazier Healthcare Partners听&补尘辫;听	77/100
240th	Genenta Science 2014, Milan (Italy), Public	Developer of lentivirus-based gene and cell therapies for cancer	$33.6M	iStarter, Growth Engine听&补尘辫;听	57/100